Featured Research

from universities, journals, and other organizations

Dual action polyclonal antibody may offer more effective, safer protection against osteoporosis

Date:
August 20, 2012
Source:
Mount Sinai Medical Center
Summary:
A new study suggests that a polyclonal antibody that blocks follicle-stimulating hormone (FSH) in mice without ovaries might offer a more effective way to prevent or arrest osteoporosis than currently available treatments.

A new study suggests that a polyclonal antibody that blocks follicle-stimulating hormone (FSH) in mice without ovaries might offer a more effective way to prevent or arrest osteoporosis than currently available treatments.

The study used a mouse model of menopause to show that an injection of a polyclonal antipeptide antibody enhances bone regeneration by simultaneously slowing bone destruction and building bone, say researchers at the Mount Sinai School of Medicine, New York. In addition, the monoclonal antibody is likely to be safer because it is cleared from the blood and is not retained in bone.

Results from the study are published online August 20 in the journal Proceedings of the National Academy of Sciences.

"Bone loss in women begins very early, at least two to three years before a woman's last period and within eight to ten years, a woman will lose 50% of her lifetime bone loss," says the study's senior investigator, Mone Zaidi, MD, Professor of Medicine and of Structural and Chemical Biology, at Mount Sinai School of Medicine in New York." It occurs painlessly, without notice up to a point where women fracture."

Zaidi, who is director, of the Mount Sinai Bone Program, at Mount Sinai School of Medicine, New York, is the senior investigator of the research that developed the polyclonal antipeptide antibody to FSH and tested it in mice whose ovaries were removed. Peptides are short chains of amino acids, and the FSH antibody is a highly specific antibody.

"A few years ago, we showed that FSH [follicle stimulating hormone] directly regulates bone by bypassing the estrogen axis," says Zaidi. FSH rises early in menopause, stimulates bone removal and negatively regulates bone formation. "By blocking FSH with the FSH-specific polyclonal antibody, we were able to block bone resorption by osteoclasts [cells that break down bone] and stimulate bone formation through osteoblasts cells [cells that build bone]."

Zaidi summed up the research team's goal: "Our aim is to find a way to prevent osteoporosis rather than simply treat established disease using medicines that are well tolerated. We believe that a future humanized monoclonal antibody to FSH is likely to be safer than existing treatments because it will not reside in the bone."

The National Institutes of Health, the U.S. Department of Veterans Affairs, and the U.S. Department of Agriculture supported the research.

Other senior Mount Sinai researchers involved in the study were Terry F. Davies, MD, Li Sun, MD, and Maria New, MD.

Researchers at the Mount Sinai Bone Program have made groundbreaking discoveries in understanding bone remodeling and developing new treatments for osteoporosis, estimated to affect 50 million women worldwide. Recently, the group has discovered the pituitary bone axis, which has revolutionized the paradigm for understanding osteoporosis.

The Mount Sinai Bone Program was established in 1999 with Dr. Zaidi as its Founding Director. It is recognized nationally and internationally for its cutting-edge translational research and highly sought after clinical work in osteoporosis and other bone diseases, including rare genetic diseases, such as Gaucher Disease. It is supported by the National Institutes of Health.


Story Source:

The above story is based on materials provided by Mount Sinai Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Ling-Ling Zhu, Harry Blair, Jay Cao, Tony Yuen, Rauf Latif, Lida Guo, Irina L. Tourkova, Jianhua Li, Terry F. Davies, Li Sun, Zhuan Bian, Clifford Rosen, Alberta Zallone, Maria I. New, and Mone Zaidi. Blocking antibody to the β-subunit of FSH prevents bone loss by inhibiting bone resorption and stimulating bone synthesis. Proceedings of the National Academy of Sciences, August 20, 2012 DOI: 10.1073/pnas.1212806109

Cite This Page:

Mount Sinai Medical Center. "Dual action polyclonal antibody may offer more effective, safer protection against osteoporosis." ScienceDaily. ScienceDaily, 20 August 2012. <www.sciencedaily.com/releases/2012/08/120820152058.htm>.
Mount Sinai Medical Center. (2012, August 20). Dual action polyclonal antibody may offer more effective, safer protection against osteoporosis. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2012/08/120820152058.htm
Mount Sinai Medical Center. "Dual action polyclonal antibody may offer more effective, safer protection against osteoporosis." ScienceDaily. www.sciencedaily.com/releases/2012/08/120820152058.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins